Stockscreener 앱 받기
66.13
7.03%
-5.00
시간 외 거래:
64.76
-1.37
-2.07%
Grail Inc 주식(GRAL)의 최신 뉴스
President Joshua Ofman Sold A Bunch Of Shares In GRAIL - simplywall.st
GRAIL (NASDAQ:GRAL) Hits New 52-Week HighHere's Why - MarketBeat
The holy grail of modern marketing - Fast Company
11,400 Shares in GRAIL, Inc. $GRAL Purchased by Trifecta Capital Advisors LLC - MarketBeat
CRCM LP Reduces Stake in GRAIL Inc.: A Strategic Portfolio Adjustment - GuruFocus
GRAIL (NASDAQ:GRAL) President Sells $5,086,562.50 in Stock - MarketBeat
Why GRAIL Inc. (NL0) stock could rally strongly2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
GRAIL (NASDAQ:GRAL) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Recent Developments Impacting GRAL - timothysykes.com
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Here's Why - MarketBeat
Do Insider Sales at GRAIL (GRAL) Hint at Shifting Management Confidence Amid Revenue Growth? - simplywall.st
GRAIL (GRAL): Evaluating Valuation After 20% Revenue Growth and Modest Share Price Gains - Yahoo Finance
Slow Capital Inc. Raises Stock Holdings in GRAIL, Inc. $GRAL - MarketBeat
GRAIL (NASDAQ:GRAL) Trading Down 4% Following Insider Selling - MarketBeat
Liquid Biopsy for Early Cancer Detection and Monitoring - GlobeNewswire
Liquid Biopsy for Early Cancer Detection and Monitoring Market Report 2025-2033, with Profiles of GRAIL, AnchorDx, Burning Rock Biotech, Genecast, Guardant Health, Elypta, Freenome, and Oncimmune - Yahoo Finance
Why GRAIL Inc. (NL0) stock stays on top picksTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
Insider Sell: Joshua Ofman Sells 9,692 Shares of GRAIL Inc (GRAL) - GuruFocus
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data! - ts2.tech
Grail price target raised to $75 from $43 at Canaccord - TipRanks
How GRAIL Inc. (NL0) stock trades under stagflationEarnings Overview Report & Fast Gaining Stock Strategy Reports - newser.com
Grail Inc stock hits all-time high of 64.0 USD By Investing.com - Investing.com Nigeria
Grail Inc stock hits all-time high of 64.0 USD - Investing.com India
GRAIL (NASDAQ:GRAL) Reaches New 1-Year HighHere's What Happened - MarketBeat
GRAIL Inc Signs New Headquarters Lease Agreement - MSN
Making Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance - MarketScreener
GRAIL Inc. (GRAL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Grail: A Speculative Buy (NASDAQ:GRAL) - Seeking Alpha
Wealth Enhancement Advisory Services LLC Acquires 6,032 Shares of GRAIL, Inc. $GRAL - MarketBeat
Will GRAL’s Latest Spike Sustain? - timothysykes.com
GRAIL (NASDAQ:GRAL) Stock Price Up 7.2%Still a Buy? - MarketBeat
Why Is GRAIL Stock Rising? - StocksToTrade
Illumina, Grail Beat Investor Suit Over Doomed Acquisition (2) - Bloomberg Law News
What drives GRAIL Inc NL0 stock priceCovered Call Writing & Hidden Gems with Outstanding Profit Margins - earlytimes.in
The European Commission prohibits and plans to unwind Illumina's acquisition of GRAIL - Norton Rose Fulbright
GRAIL, Inc. (GRAL): A Bull Case Theory - MSN
What drives GRAIL LLC stock priceInsider Buying Signals & Compound Your Gains With Quality Stocks - Early Times
Illumina And Grail Nix Investor Suit Over Failed Deal, For Now - Law360
This Cancer Detection Pioneer Is Worth a Look - Yahoo Finance
Is GRAIL LLC stock attractive after correctionSwing Trade & High Conviction Investment Ideas - newser.com
Will Rising Galleri Adoption Drive Growth For GRAIL Stock? - RTTNews
Dakota Wealth Management Makes New Investment in GRAIL, Inc. $GRAL - MarketBeat
GRAIL to Showcase New Data for Galleri Multicancer Early Detection Test at Key Fall Meetings - Patient Care Online
GRAIL to Present New Galleri® Data From More Than 32,000 Partici - GuruFocus
GRAIL to present first PATHFINDER 2 results at ESMO Congress By Investing.com - Investing.com South Africa
GRAIL to present first PATHFINDER 2 results at ESMO Congress - Investing.com
GRAIL to Present New Galleri® Data From More Than 32,000 Participants Across the PATHFINDER 2, SYMPLIFY and REFLECTION Studies at ESMO Congress 2025 and EDCC - MarketScreener
32,000-Patient Study: GRAIL's Blood Test Doubles Early Cancer Detection Rate in Landmark Research - Stock Titan
GRAIL (NASDAQ:GRAL) Trading 7.2% HigherStill a Buy? - MarketBeat
0.17%
2.19%
자본화:
|
볼륨(24시간):